205654-37-1
|
|
- CAS号:
- 205654-37-1
- 英文名:
- Urea, N'-[[2-[2-[(4-chlorophenyl)thio]ethoxy]-3-methoxy-5-[(2S,5S)-tetrahydro-5-(3,4,5-trimethoxyphenyl)-2-furanyl]phenyl]methyl]-N-hydroxy-N-methyl-
- 英文别名:
- CMI 392,CMI392;Urea, N'-[[2-[2-[(4-chlorophenyl)thio]ethoxy]-3-methoxy-5-[(2S,5S)-tetrahydro-5-(3,4,5-trimethoxyphenyl)-2-furanyl]phenyl]methyl]-N-hydroxy-N-methyl-
- 中文名:
- 205654-37-1
- 中文别名:
- 化合物 T10844;化合物 CMI-392
- CBNumber:
- CB93339724
- 分子式:
- C31H37ClN2O8S
- 分子量:
- 633.15
- MOL File:
- 205654-37-1.mol
|
|
|
205654-37-1化学性质
-
密度:
-
1.35±0.1 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
Soluble in DMSO
-
|
-
酸度系数(pKa):
-
9.82±0.50(Predicted)
-
|
205654-37-1性质、用途与生产工艺
CMI-392是一种双重 5-lipoxygenese 抑制剂和血小板活化因子 (PAF) 受体拮抗剂,IC50 值分别为100和10 nM。
5-LO
100 nM (IC
50
)
|
PAF
10 nM (IC
50
)
|
Topical treatment of CMI-392 in the acute and chronic TPA models result in a significant decrease of ear weight, inflammatory cell infiltration, and histological examination. The ED
50
for PAF-induced mouse hemoconcentration and arachidonic acid-induced mouse ear edema are 2.2 and 1.8 mg/kg, respectively.
205654-37-1
上下游产品信息
上游原料
下游产品
205654-37-1, 205654-37-1 相关搜索:
- 抑制剂
- C31H37ClN2O8S
- 化合物 CMI-392
- 化合物 T10844
- 205654-37-1
- CMI 392,CMI392
- Urea, N'-[[2-[2-[(4-chlorophenyl)thio]ethoxy]-3-methoxy-5-[(2S,5S)-tetrahydro-5-(3,4,5-trimethoxyphenyl)-2-furanyl]phenyl]methyl]-N-hydroxy-N-methyl-